Cargando…
Prescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis
BACKGROUND: Ranitidine was the most prescribed histamine-2 receptor antagonist (H(2)RA) in Canada when recalled in 2019 because of potential carcinogenicity. We sought to compare geographic and temporal patterns in use of prescription ranitidine and 3 other HRAs and estimated population exposure to...
Autores principales: | Levy, Adrian R., Stock, David, Paterson, J. Michael, Tamim, Hala, Chateau, Dan, Quail, Jacqueline, Ronksley, Paul E., Carney, Greg, Reynier, Pauline, Targownik, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635705/ https://www.ncbi.nlm.nih.gov/pubmed/37935487 http://dx.doi.org/10.9778/cmajo.20220131 |
Ejemplares similares
-
Pharmacokinetics of ranitidine during hemodiafiltration
por: Fuhrmann, V, et al.
Publicado: (2008) -
Medicine and Media: The Ranitidine Debate
por: Wagner, Jennifer A., et al.
Publicado: (2020) -
Ranitidine anaphylaxis: A rare occurrence
por: Vyas, Varsha H, et al.
Publicado: (2011) -
Ranitidine-induced galactorrhea: Exploring the intricacies
por: Ray, Avik, et al.
Publicado: (2020) -
Fatal injection of ranitidine: a case report
por: Oliva, Antonio, et al.
Publicado: (2008)